LRA3-1

........10........20........30........40........50........60........70........80........90.......100.......110.......120.......130.......140.......150.......160.......170.......180.......190.......200.......210.......220.......230.......240.......250.......260.......270.......280.......290.......300.... MKSKLLLAAALAALAGTSMAAQAAELQYKPPPITNKEWETPFPGFKIVGNMYYVGTYDLGCYLIDTGAGLILINSGADGSYPLIKANIEKLGFKTSDIKIITSTHGHGDHVGDLAAFQKDAPAAKTYMNFRDAPTIESGGNIDYRRPEGRGFYPYHPVKVDVRTKPGDHIKLGNTDLTLHQAYGHTPGATSFTFTVQDGGRNYNVLIVNMNGINAGVKLLGSPGYPTIVEDFASTLKEQATYTPDLWVSSHAGQFNLHQVYKPGDPYNPARFGDLAAYKLKIANATKAYEKQLAEERAAKAK--

LRA3-2

.R.....TV..V-..AA.AP..............................L.............................................E.....A..........................E.....L..............................................F............T..A...............Q..............................I......................................L................AVR

92.43 %

Last updated: January 08, 2024.

If you use BLDB please cite: Naas, T.; Oueslati, S.; Bonnin, R. A.; Dabos, M. L.; Zavala, A.; Dortet, L.; Retailleau, P.; Iorga, B. I., Beta-Lactamase DataBase (BLDB) – Structure and Function. J. Enzyme Inhib. Med. Chem. 2017, 32, 917-919.

The development of the BLDB database is funded in part by the JPIAMR transnational project DesInMBL, the Région Ile-de-France (DIM Malinf) and the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT).

Contact: contact@bldb.eu

Live statistics (since December 3rd, 2023)